Skip to main content

Spastic Paraparesis Type 7

  • 1340 Accesses

Abstract

Hereditary spastic paraplegia (SPG) is a group of neurodegenerative disorders characterized by progressive spasticity and weakness of the lower limbs, resulting from “dying back” axonopathy of the corticospinal tract. Pure and complicated forms are known, and loci with autosomal dominant, recessive, and X-linked patterns of inheritance were identified.

SPG7 is characterized by insidiously progressive bilateral lower limb weakness and spasticity (Tables 82.1 and 82.2). Most affected individuals have proximal or generalized weakness in the legs and impaired vibration sense. Onset is mostly in adulthood (ranging from 11 to 72 years). Clinical features of the disease include lower limb spasticity and weakness, spastic ataxic gait, hyperreflexia, extensor plantar responses, pyramidal signs, decreased vibratory sense in the lower limbs, degeneration of the lateral corticospinal tracts, cerebral white matter lesions, dysarthria, cognitive and memory deficits, cortical atrophy, and cerebellar atrophy. Additional features such as sphincter disturbances, dysphagia, pale optic disks, retinitis pigmentosa, nystagmus, strabismus, decreased hearing, scoliosis, and pes cavus may be observed. The disease is caused by mutations in the PGN gene, encoding paraplegin protein. The protein is located within the inner membrane of mitochondria and forms a complex called the m-AAA protease, which is responsible for assembling ribosomes and removing nonfunctional proteins in the mitochondria. Nonfunctional m-AAA proteases cause a buildup of unusable proteins in nerve cells, resulting in swelling of the cell, and reduced cell signaling and movement. Since the first molecular characterization, a number of patients have been clinically and genetically defined.

Keywords

  • Spastic paraparesis
  • Paraplegin

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-07500-6_82
  • Chapter length: 4 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   59.99
Price excludes VAT (USA)
  • ISBN: 978-3-319-07500-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Fig. 82.1

References

  1. Casari G, De Fusco M, Ciarmatori S, et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell. 1998;93:973–83.

    CAS  PubMed  CrossRef  Google Scholar 

  2. Arnoldi A, Tonelli A, Crippa F, et al. A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat. 2008;29:522–31.

    CAS  PubMed  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Angelini, C. (2014). Spastic Paraparesis Type 7. In: Genetic Neuromuscular Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-07500-6_82

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-07500-6_82

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-07499-3

  • Online ISBN: 978-3-319-07500-6

  • eBook Packages: MedicineMedicine (R0)